Omar Halawi/iStock via Getty Images I upgraded Becton, Dickinson and Company's (NYSE:BDX) to a 'Buy' rating in my previous article published in March 2024, arguing major growth challenges including Alaris pump and strong year-over-year comparables were fading away. I believe GLP-1 drug delivery could become a significant growth driver for the company in the near future. The company announced to acquire Edwards Lifesciences' (EW) Critical Care product group for $4.2 billion. I view the acquisition as value a ...

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies Higher do ...

TAMPA, Fla., Sept. 4, 2024 /PRNewswire/ -- Integrated Ventures Inc. (OTCQB: INTV), a holdings company, focused on e-commerce technology, digital assets and consumer-focused investments, is excited to announce (1) formation and launch of our second, fully funded, 100% owned subsidiary - MedWellDirect, LLC, Direct-ToConsumer (D2C) telemedicine solutions provider, mainly for weight loss and GLP-1 products and (2) acquisition of 51% stake in GetTrim.Com (TM), owned by Healthy Lifestyle USA – an innovative telem ...

The advent of GLP-1 weight-loss treatments has inadvertently underscored the importance of protein in mitigating muscle loss. While taking GLP-1 meds may be out of reach of many consumers due to exorbitant out-of-pocket costs and limited health insurance coverage, the popularity of high protein diets like keto or carnivore continues to gain popularity as a natural method to lose weight. Adding beef can reap rewards to a diet, but it's also proven to reap financial rewards for retail/wholesale sector restaur ...

Tim Platt/DigitalVision via Getty Images Thesis Viking Therapeutics (NASDAQ:VKTX) is a biotechnology company in the clinical stage focused on the discovery and development of novel treatments for metabolic and endocrinology disorders. Viking's most promising program is VK2735, a dual agonist (activator) of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is aimed for the treatment of obesity, and it accounts for two formulations currently being tested ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and wellness and biotech stocks issues a snapshot looking at news and developments for the global GLP-1 receptor agonist market, featuring new player in the market, Integrated Ventures, Inc. (OTCQB: INTV). Read the full article at Investorideas.com https://www.investorideas.com/News/2024/biotech/08280GLP-1.asp According to Research and Markets, The global GLP-1 ...

TAMPA, Fla. , Aug. 28, 2024 /PRNewswire/ -- Integrated Ventures, Inc. (OTCQB: INTV), a diversified portfolio holdings company, is excited to announce its strategic entry into the rapidly expanding health and wellness sector. The initial phase of this transition will be led by the newly established subsidiary, MedWell USA, LLC, which will serve as a B2B Procurement Agent for a variety of pharmaceutical products, with a particular focus on the booming medical weight loss and GLP-1 markets. MedWell USA will be ...

SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy® and compounded semaglutide through a weight loss program on its telehealth platform, providing consumers with access to affordable weight management care through a convenient subscription-based model. If prescribed, Lemonaid Health patients will now have access to once-weekly injectable GLP-1 medication offerings ...

Ozempic remains on top in the GLP-1 drug market -- but for how long? The anti-obesity drug market could one day be worth $100 billion. It's a massive opportunity in healthcare, and two companies that are leaders in that space today are Eli Lilly (LLY 0.23%) and Novo Nordisk (NVO 1.42%). Unsurprisingly, these are also two of the most valuable healthcare companies in the world right now. They have been rivals for decades, and the growing popularity of their respective glucagon-like peptide 1 (GLP1) drugs ensu ...

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, has started screening patients for a Phase 2 clinical trial (CBeyondTM) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a nextgeneration weight loss therapeutic to safely and effectively reduce weight in patients w ...